Quality of life in diffuse large B-cell lymphoma patients treated with dose-dense chemotherapy is only affected temporarily
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Quality of life in diffuse large B-cell lymphoma patients treated with dose-dense chemotherapy is only affected temporarily. / Tholstrup, D; Brown, Peter; Jurlander, Jesper; Jeppesen, PB; Grønvold, Mogens.
I: Leukemia and Lymphoma, Bind 52, Nr. 3, 2011, s. 400-408.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Quality of life in diffuse large B-cell lymphoma patients treated with dose-dense chemotherapy is only affected temporarily
AU - Tholstrup, D
AU - Brown, Peter
AU - Jurlander, Jesper
AU - Jeppesen, PB
AU - Grønvold, Mogens
PY - 2011
Y1 - 2011
N2 - R)-CHOP-14 has substantially improved outcome in DLBCL, but may have increased morbidity and reduced quality of life (QoL). Our aim was to evaluate QoL during (R)-CHOP-14-based chemotherapy. Twenty-six patients participated (small single-center study). EORTC QLQ-C30 was completed pre-treatment, mid-treatment, 14 days post-treatment, and 3 months post-treatment. Scores were compared to a reference population, and analyzed separately. Pre-treatment, global health status (p¿=¿0.004), physical functioning (p¿=¿0.036), role functioning (p¿=¿0.017), and emotional functioning (p¿=¿0.040) were reduced, and fatigue (p¿=¿0.009) and appetite loss (p¿=¿0.007) increased compared to the reference population. During treatment, physical functioning and role functioning decreased significantly, whereas emotional functioning, fatigue, and diarrhea increased. Three months post-treatment, scores were generally equivalent to those of the reference population, and lower for nausea/vomiting (p¿<¿0.001) and constipation (p¿<¿0.001). Disease-related symptoms were frequent in high-risk DLBCL. Treatment-related symptoms were normalized 3 months post-treatment. In conclusion, QoL is only temporarily affected during (R)-CHOP-14-based chemotherapy, and the treatment regimen is therefore feasible.
AB - R)-CHOP-14 has substantially improved outcome in DLBCL, but may have increased morbidity and reduced quality of life (QoL). Our aim was to evaluate QoL during (R)-CHOP-14-based chemotherapy. Twenty-six patients participated (small single-center study). EORTC QLQ-C30 was completed pre-treatment, mid-treatment, 14 days post-treatment, and 3 months post-treatment. Scores were compared to a reference population, and analyzed separately. Pre-treatment, global health status (p¿=¿0.004), physical functioning (p¿=¿0.036), role functioning (p¿=¿0.017), and emotional functioning (p¿=¿0.040) were reduced, and fatigue (p¿=¿0.009) and appetite loss (p¿=¿0.007) increased compared to the reference population. During treatment, physical functioning and role functioning decreased significantly, whereas emotional functioning, fatigue, and diarrhea increased. Three months post-treatment, scores were generally equivalent to those of the reference population, and lower for nausea/vomiting (p¿<¿0.001) and constipation (p¿<¿0.001). Disease-related symptoms were frequent in high-risk DLBCL. Treatment-related symptoms were normalized 3 months post-treatment. In conclusion, QoL is only temporarily affected during (R)-CHOP-14-based chemotherapy, and the treatment regimen is therefore feasible.
KW - Faculty of Health and Medical Sciences
KW - Lymphoma
KW - quality of life
U2 - 10.3109/10428194.2010.541310
DO - 10.3109/10428194.2010.541310
M3 - Journal article
C2 - 21250826
VL - 52
SP - 400
EP - 408
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 3
ER -
ID: 33172389